Cytokinetics said it has received MHRA marketing authorisation for MYQORZO (aficamten) and positive guidance from NICE for patients with symptomatic obstructive hypertrophic cardiomyopathy in England and Wales. The update combines a regulatory milestone with a favorable assessment that can shape patient access.
The announcement points to two important steps in the UK pathway for the treatment. MHRA authorisation means the medicine has cleared the regulator’s review, while positive NICE guidance supports its use for eligible patients within England and Wales.
Symptomatic obstructive hypertrophic cardiomyopathy is a heart condition that can significantly affect daily life, so decisions from both MHRA and NICE are closely watched by clinicians, patients and investors. In this case, the pairing of authorisation and positive guidance suggests meaningful progress for MYQORZO in a major healthcare market.
Cytokinetics, which issued the announcement from South San Francisco, presented the news for business, financial media and investors. For the company, the development marks an important commercial and regulatory advance for aficamten in the UK setting.
